Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

Our range of services cover phases I, II and III ECG safety studies for cardiovascular and non-cardiovascular compounds.

Many "normal" healthy volunteers will have abnormal ECGs or have abnormal ECGs which they are aware of. These abnormal ECGs may have a big impact on the development of a new chemical entity if the data obtained is not scrutinised properly at an early stage.

Early signal detection and full follow up by Richmond Pharmacology's cardiology team is essential to ensure that the digital ECG data obtained from an early phase trial is analysed and reported appropriately. Richmond Pharmacology has the capacity to undertake and subsequently analyse several cardiological assessments to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Analysis services include rest and exercise ECG analysis, detailed digital QT analysis, entry criteria validation, cardiac event classification and Holter provision, analysis and review. The assessments are performed using Richmond's bespoke and integrated MUSE setup.

We ensure rapid and reliable digital ECG data is obtained to support the “go” or “no-go” decisions during your early phase trial.

Get in touch today

Latest news

リッチモンド社、Beam Therapeuticsと共にα1アンチトリプシン欠乏症(AATD)の画期的な試験を実施

April 1, 2025
リッチモンドは、Beam Therapeutics が実施中の第1/2相試験において、α1アンチトリプシン欠乏症(AATD)の新たな治療法候補に関する最初の3つの用量レベルの予備的結果が得られたことを発表
Read more

リッチモンド、サステナビリティ・アクセラレータープログラムを通じてESGへの取り組みを強化  

March 31, 2025
私たちは、責任ある持続可能なビジネス成長を促進するために、環境・社会・ガバナンス(ESG)の原則を臨床研究業務に組み込むことに取り組んでいます。
Read more

Events

CRISPR Medicine 2025: Unlocking Gene-Editing Potential

April 7–11
Exploring advancements shaping the future of healthcare.
View event